Yunnan-based KPC Pharmaceuticals Inc., (SHA: 600422) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its Category 2.2 product KPC-149, which is intended for the treatment of familial Mediterranean fever (FMF).
FMF is an autosomal recessive autoimmune disease associated with mutations in the MEFV gene, also known as the Mediterranean fever gene. It is characterized by recurrent self-limited fever and various serositis, including peritonitis, pleurisy, pericarditis, and arthritis. FMF is recognized as a rare disease in China and is included in the first rare disease list issued by the country. Currently, the only treatment available in the market is Sobi’s Kineret (anakinra). – Flcube.com
